The transformative role of agentic AI in accelerating clinical trial workflows and improving decision-making precision in life sciences research

In the rapidly changing field of life sciences, clinical trials play an important role in developing new therapies and bringing effective treatments to patients. However, managing these trials involves complex workflows, large amounts of data, and a need for accurate decision-making. Recently, agentic artificial intelligence (AI) has become an important tool that can improve clinical trial workflows and help make decisions faster and more accurately in life sciences research, especially in the United States where healthcare is always looking for new ways to be efficient and innovative.

Understanding Agentic AI in Life Sciences

Agentic AI is different from regular AI systems in healthcare and life sciences because it acts like an independent partner with goals, not just a helper tool. Normal AI usually helps with tasks like recognizing images or entering data, but agentic AI can manage complicated processes with little human input. It can plan, analyze, learn, and carry out tasks while explaining its decisions, working almost like a virtual teammate.

In clinical trials, agentic AI can handle many parts of the research process on its own. This includes finding targets for new drugs, looking over large amounts of clinical data, doing literature reviews, and working with healthcare professionals (HCPs). For organizations running trials in the United States, this can save a lot of time and resources by speeding up work, cutting down on manual tasks, and making sure rules are followed.

The Impact of Agentic AI on Clinical Trial Workflows

Clinical trials often need people to coordinate patient recruitment, data gathering, risk checking, and paperwork. These steps take time and can have errors. Agentic AI helps fix these problems through automation and smart data analysis.

Research from companies like IQVIA and ConcertAI shows that agentic AI can automate about 85% of tasks in the pharmaceutical industry, including managing trials. This automation cuts down the time needed by 25-35%, allowing trials to finish faster without lowering data quality or patient safety.

For example, IQVIA worked with NVIDIA to create AI agents using NVIDIA’s technologies like NIM Agent Blueprints and NeMo Customizer. These agents make workflows smoother by quickly scanning thousands of scientific papers and clinical records. This speeds up drug discovery and clinical trial planning by combining healthcare knowledge with powerful AI tools.

Novartis, a large pharmaceutical company in the United States, uses generative AI platforms like Causaly to speed up finding targets and forming hypotheses. This method is five times more productive than traditional ways like PubMed searches. By automating routine data reviews, researchers can spend more time understanding results. This helps research and reduces the time it takes to bring new treatments to market.

Improving Decision-Making Precision with Agentic AI

In life sciences research, making the right decisions is very important for trial success, patient safety, and following rules. Agentic AI helps make precise decisions by giving real-time, evidence-based insights from large and combined data sets.

Agentic AI can process different types of data—such as clinical trial results, patient records, scientific articles, and market information—which improves the accuracy of risk checks, safety evaluations, and patient grouping. This lowers the chances of clinical trial failures, which are costly and common in drug development.

ConcertAI’s CARAai™ platform uses agentic AI in cancer research. It combines data from over 5.5 million cancer patient records, allowing doctors and researchers to make quick, informed decisions. This helps spot safety issues earlier and design trials with better chances of success.

Research from McKinsey shows that using agentic AI can increase companies’ revenue growth by 5-13 percentage points and improve profit margins by 2-5 points within three to five years. These gains come from faster clinical development, fewer delays, and better use of resources.

AI-Enabled Workflow Automation in Clinical Trials

AI in clinical workflows supports many automation tasks that improve efficiency and reduce work pressure. This section focuses on how AI-driven automation improves operations in clinical trials.

Agentic AI can manage patient recruitment by scanning electronic health records (EHRs) to find eligible participants, making recruitment faster. It can also watch over data collection by automatically noticing mistakes or missing information, which improves quality and rule compliance.

Beyond individual trials, AI-based Laboratory Information Management Systems (LIMS) use agentic AI to automate routine lab tasks such as designing experiments, finding risks, and managing paperwork. This lets lab workers focus on more advanced analysis, improving accuracy and cutting costs.

AI algorithms also help predict resource problems and organize equipment schedules better. For example, agentic AI can quickly adjust workflows without human input when trial conditions or regulations change.

In the United States, healthcare systems often mix old systems with new technology. Using AI automation here needs careful planning, good data management, and training for staff. Organizations must create rules to make sure AI processes follow FDA regulations and protect patient privacy.

Adoption Challenges and Organizational Impact

Using agentic AI in life sciences and clinical trials comes with some challenges, especially for medical practice administrators, owners, and IT managers in the US. One big challenge is data fragmentation. Many organizations have information stuck in separate systems, with about 78 different systems used in healthcare settings. This limits data sharing, which slows down AI effectiveness and timely insights.

Managing change is also important. Staff need to learn how to use AI platforms and oversee workflows where AI handles routine tasks, and humans use judgement. Successful adoption requires strong leadership, AI knowledge, and legal oversight to ensure responsible and ethical AI use.

Leadership support is key. McKinsey research says companies that use agentic AI well have better competitiveness and flexibility. This involves moving from old growth methods with more staff and manual work to streamlined, AI-powered approaches that improve teamwork and reduce regulatory load.

Real-world Clinical AI Applications in the United States

• IQVIA uses agentic AI agents made with NVIDIA’s tools to speed up clinical trial planning, literature review, and working with healthcare professionals. This helps achieve more accurate clinical results in drug development.
• Novartis uses AI tools like Causaly to help US discovery teams quickly understand large amounts of biomedical literature and create better scientific ideas, increasing research speed.
• ConcertAI built an oncology data cloud using real-world data from 5.5 million patient records via CancerLinQ®. Their AI platforms use agentic AI microservices developed with NVIDIA, improving trial design and execution with clear AI models that meet FDA standards.
• Novo Nordisk, a global company, has created multiagent AI frameworks ready for production that handle large workflow automation and decision-making in the US healthcare system.

Regulatory and Ethical Considerations

In the US, agencies like the FDA require high standards for AI in clinical trials to protect patients and ensure data quality. Companies like ConcertAI have made AI models clear, balanced, and explainable. They follow “Context of Use” rules and use neutral real-world data to meet regulations and reduce AI bias.

Ethical use means balancing automation benefits with human oversight. Life sciences companies must create value-based systems that include patient opinions and proper scientific measures when checking AI impact, not just short-term cost savings. This helps build trust and ensures AI is used responsibly.

Future Outlook

Experts predict faster AI adoption in US life sciences. By 2027, up to half of companies may use agentic AI in everyday work, handling about 15% of routine decisions. As AI improves, medical practice administrators, owners, and IT managers will focus more on managing human-AI teams and making sure AI works with rules and operations.

Agentic AI’s effects in research, clinical workflows, and patient care are expected to help drug discovery move faster, improve treatments, and make clinical trials more sustainable.